Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (CTMX) announced that it will present preclinical data on its conditionally activated cytokine program at the AACR Annual Meeting from April 8-13, 2022. The data highlights the development of the interferon alpha-2b therapeutic candidate, which aims to enhance the effectiveness of immunotherapy while reducing toxicity. This initiative is part of CytomX's broader strategy to improve treatment options for patients with challenging cancers. The presentation is scheduled for April 11, 2022, and will focus on the therapeutic candidate's potential benefits.
CytomX Therapeutics reported its 2021 financial results on March 1, 2022, highlighting significant progress in its oncology pipeline. The company is advancing Phase 2 studies for praluzatamab ravtansine and CX-2029, with initial data expected in late 2022. Cash and investments totaled $305.2 million, down from $316.1 million in 2020. Total revenues fell to $69.6 million for 2021, primarily due to a $40 million milestone payment in 2020. R&D expenses increased to $114.2 million, reflecting greater clinical trial activity. CytomX is focused on executing its pipeline in 2022.
CytomX Therapeutics (Nasdaq: CTMX) will feature CEO Sean McCarthy in a virtual panel at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 12:50 p.m. ET. The event will focus on conditionally activated oncology therapeutics.
Investors can access a live webcast via the CytomX website, with an archived replay available for 30 days post-event. The company is committed to innovating cancer treatments using its Probody technology platform, with ongoing Phase 2 studies targeting difficult-to-treat cancer types.
CytomX Therapeutics (CTMX) will report its fourth quarter and full year 2021 financial results on March 1, 2022, after U.S. market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide updates. CytomX focuses on oncology therapeutics, notably through its Probody® technology. Its pipeline includes investigational drugs like praluzatamab ravtansine and CX-2029, both undergoing Phase 2 studies for advanced cancer types. Interested parties can access the conference call via the company’s website.
CytomX Therapeutics (CTMX) announced on February 16, 2022, the granting of stock options to nine new employees, totaling 189,400 shares at an exercise price of $4.08. This grant was made under the 2019 Employment Inducement Incentive Plan, approved in August 2020, aimed at attracting new talent. CytomX focuses on conditionally activated oncology therapeutics, with a pipeline that includes investigational therapies for challenging cancer types, including praluzatamab ravtansine and CX-2029, which are currently in Phase 2 clinical studies.
CytomX Therapeutics (Nasdaq: CTMX) has promoted Amy C. Peterson, M.D., to president and chief operating officer, effective immediately. Dr. Peterson, previously the executive vice president and chief development officer, brings extensive experience in oncology development. CEO Sean McCarthy highlighted her contributions in advancing CytomX's Probody Therapeutic pipeline. In her new role, Dr. Peterson aims to enhance the company’s impact on cancer treatment through innovative strategies and leadership. CytomX continues to focus on developing conditionally activated biologics to improve cancer treatment outcomes.
CytomX Therapeutics (Nasdaq: CTMX) announced on January 18, 2022, the granting of stock options for 127,000 shares to four new employees at an exercise price of $3.83 per share. These options are part of the 2019 Employment Inducement Incentive Plan approved by the Company’s board in August 2020. CytomX specializes in conditionally activated therapeutics, focusing on various oncology treatments, particularly through its Probody technology platform. The company’s current clinical pipeline includes several investigational drugs aimed at treating difficult cancer types.
CytomX Therapeutics announced FDA clearance of the IND application for CX-904, its first T-cell-engaging bispecific antibody and sixth Probody candidate to enter clinical trials. Co-developed with Amgen, CX-904 is targeted at treating advanced solid tumors by selectively engaging T cells in the tumor microenvironment. The company emphasizes the innovative aspects of CX-904, which shows potent anti-tumor activity in preclinical studies and aims to initiate a Phase 1 dose-escalation study soon. CytomX aims to redefine cancer treatment with its conditionally activated therapeutics.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12 at 3:00 p.m. ET. The presentation will be available live on CytomX’s website, with an archived replay accessible for 30 days post-event. CytomX is known for its innovative conditionally activated biologics aimed at enhancing cancer treatment. Their pipeline includes investigational therapies like praluzatamab ravtansine and CX-2029, currently in Phase 2 studies targeting hard-to-treat cancers.
CytomX Therapeutics (CTMX) announced preliminary Phase 2 results for CX-2029, an antibody-drug conjugate targeting advanced squamous non-small cell lung cancer (sqNSCLC) and head and neck squamous cell carcinoma (HNSCC). In sqNSCLC, the objective response rate (ORR) was 18.8%, with a disease control rate (DCR) of 87.5%. HNSCC patients showed an ORR of 4.0% and a DCR of 56.0%. No new safety signals were detected, maintaining a favorable adverse event profile. The company continues to enroll patients and is optimistic about future data releases.